HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.1%

Neg 0% Neu 92.1% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 price target.